A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris


Authors : Therese Anne Limbana OMS; Caleb Sooknanan OMS; Maria Pino

Volume/Issue : Volume 9 - 2024, Issue 5 - May

Google Scholar : https://tinyurl.com/bdz669vz

Scribd : https://tinyurl.com/yc5tj52k

DOI : https://doi.org/10.38124/ijisrt/IJISRT24MAY1484

PlumX Metrics

Semantic Scholar

ResearchGate

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Lichen planopilaris (LPP) is an inflammatory variant of primary cicatricial alopecia. It causes severe hair loss and can lead to complete baldness. It is an autoimmune disease and can affect patients’ physical and mental lives greatly. JAK Inhibitors have been proven the most effective treatment option to treat LPP. This literature review aimed to analyze the effectiveness of JAK inhibitors in the management of LPP. In this review, we analyzed the ten most recent and comprehensive studies. The review has summarized existing case reports from clinical studies that have supported JAK inhibitors. The findings of the review show that JAK inhibitors are effective options for the treatment of LPP, however, there are still some concerns regarding the long-term safety of these drugs in the treatment of LPP. This review also highlights potential gaps in the literature and further need for research. Currently, there is a need for further research on the effectiveness of JAK inhibitors in the treatment of LPP.

Keywords : Lichen Planopilaris, Scarring Alopecia, Janus Kinase Inhibitors, Tofacitinib, Ruxolitinib, Baricitinib.

References :

  1. Linchen Planopilaris. 2023.
  2. Lichen Planopilaris: retrospective study on the characteristics and treatment of 291 patients. Journal of Dermatological Treatment. 2019.
  3. The efficacy and use of finasteride in women: A systematic review. International Journal of Dermatology. 2019, 58:759-776.
  4. The uses of naltrexone in dermatologic conditions. Journal of the American Academy of Dermatology. 2019, 80:1746-1752.
  5. Central Frontoparietal Band-Like Alopecia in a 40-year-old-woman. Skin Appendage Disorders. 2018, 4:351-353.
  6. Cisatricial (scarring) alopecias: an overview of pathogenesis, classification, diagnosis, and treatment. American Journal of Clinical Dermatology. 2012, 13:247-260.
  7. Lichen Planopilaris: update on diagnosis and reatment. In Seminars in cutaneous medicine and surgery. 2009, 28:3-10.
  8. Clinical severity does not realiably predict quality of life in women with  alopecia areata, telogen effluvium, or androgenic alopecia. Journal of the Amarican Academy of Dermatology. 2012, 66:e97-e102.
  9. Quality of life and mental health status in patients with Lichen Planopilaris based on Dermatology Life Quality Index and General Health Questionnaire-28 questionnaires. International Journal of Women's Dermatology. 2020, 6:399-403.
  10. JAK Inhibitors in the Treatment of Lichen Planopilaris Skin Appendage Disorders. 2024:1-8.
  11. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. Journal of the American Academy of Dermatology. 2017, 76:22-28.
  12. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI insights. 2016, 1.
  13. JAK inhibitors in Lichen planus: a review of pathogenesis and treatments. Journal of Dermatological Treatment. 2022, 33:3098-3103.
  14. Jenus kinase inhibitors: a review of their emerging applications in dermatology. Skin therapy letter. 2018, 23:5-9.
  15. IFN-Y enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Science translational medicines. 2019, 11:eaav7561.
  16. The use of Janus kinase inhibitors for lichen planus: an evidence-based review. Journal of Cutaneous Medicine and Surgery. 2023, 27:271-276.
  17. Tofacitinib for the treatment of lichen planopilaris : a case series. Dermatological Therapy. 2018, 31:e12656.
  18. Nasimi M, Ahangari N, Lajevardi V, Mahmoudi H, Ghodsi SZ, Etesami I: Quality of life and mental health status in patients with lichen planopilaris based on Dermatology Life Quality Index and General Health Questionnaire-28 questionnaires. Int J Womens Dermatol. 2020, 6:399-403. 10.1016/j.ijwd.2020.09.005
  19. Incidence of squamous cellcarcinoma in oral lichen planus: a 25-year population-based study. International Journal of Dermatology. 2019, 58:296-301.
  20. Lichen Planopilaris: update on diagnosis and treatment. In seminars in cutaneous medicine and surgery. 2009, 28:3-10.
  21. Short course of oral cyclosporine in lichen planopilaris. Journal of the American Academy of Dermatology. 2003, 49:667-671.
  22. Primary cicatrical alopecia: lumphocytic primary cicatricial alopecias, including chronic cutaneous lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia, and Grahan-Little syndrom. Journal of the American Academy of Dermatology. 2016, 75:1081-1099.
  23. A case series of 46 patients with lichen planopilaris: demographics, clinical evaluation, and treatment experience. Journal of Dermatological Treatment. 2015, 26:275-279.
  24. Treatment of frontal fibrosing alpecia and lichen planopilaris: a systematic review. Journal of the European Academy of Drmatology and Venereology. 2013, 27:1461-1470.
  25. Successful Treatment of Eruptive Lichen Planus in a Male Adult with Janus Inhibitor Tofacitinib. Arc Clin Exp Dermatol. 2023, 5:151.
  26. Lichen Planopilaris is characterized by immune privilage collapse of the hair follicle's stem cell niche. The Journal of Pathology. 2013, 231:236-247.
  27. Lichen planopilaris. Dermatologic Therapy. 2008, 21:249-256.
  28. Lichen planopilaris treated with a peroxisome proliferator-activated receptor y agonist. Archives of dermatology. 2009, 145:1363-1366.
  29. Female pattern hair loss: a clinical and pathophysiological review. Anais brasileiros dee dermatologia. 2015, 90:529-543.
  30. Update on primary cicatricial alopecias. Journal of the American Academy of Dermatology. 2005, 53:1-37.
  31. Lichen planopilaris with pustules: a diagnostic challenge. Skin Appendage Disorders. 2018, 4:61-66.
  32. Literature Review of treatment outcomes for lichen planus pigmentosus, erythema dyschromicum perstans, and ashy dermatosis. Journal of Cutaneous Medicines and Surgery. 2018, 22:643-645.
  33. Nnoruka EN: Lichen planus in african Children: a study of 13 patients. Pediatric Dermatology. 2007, 24:495-498.
  34. Lichen planopilaris in women: a retrospective review of 232 women seen at Mayo Clinic from 1992 to 2016. In Mayo  Clinic Proceedings. 2020, 95:1684-1695.
  35. Long-term safety profile and off-label use of JAK inhibitors in dermatological disorders. Actas dermo-sifiliograficas. 2023.
  36. Esophageal lichen planus successfully treated with the JAK 1/3 inhibitor tofacitinib. JDDG: Jouranl der Deutschen Dermatologischen Gesellschaft. 2022, 20:858-860.
  37. Treatment of lichen planopilaris with baricitinib: a retrospective study. Journal of the American Academy of Dermatology. 2022, 87:663-666.
  38. Janus Kinase inhibitors for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature. JAAD Case Reports. 2023, 40:47-52.
  39. Atopic dermatitis in skin of colour. Part 2: considerations in clinical presentation and treatment options. Clinical and Experimental Dermatology. 2023, 48:1091-1101.
  40. 16 th Medical Dermatology Meeting. Virtual Abstracts. 2021.
  41. Treatment of severe lichen planus with the JAK inhibitors tofacitinib. Journal of Allergy and Clinical Immunology. 2020, 145:1708-1710.
  42. Gravante F, Giannarelli D, Pucci A, et al.: Prevalence and risk factors of delirium in the intensive care unit: an observational study. Nursing in critical care. 2021, 26:156-165.
  43. Scoping Review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatology and Therapy. 2019, 79:535-544.
  44. Topical janus kinase inhibitors: a review of applications in dermatology. Journal of the American Academy of Dermatology. 2018, 79:535-544.
  45. Successful treatment of nail lichen planus with tofacitinib: a case report and review of literature. Frontiers in Medicine. 2023, 10:1301123.
  46. Commentary: a stepwise approach to the treatment of lichen planopilaris. Journal of Dermatology and Skin Diseases. 2020, 2.
  47. Successful treatment of resistant plantar ulcerative lichen planus with tofacitinib: A case report and comprehensive review of the literature. Clinical Case Reports. 2023, 11:e8066.

Lichen planopilaris (LPP) is an inflammatory variant of primary cicatricial alopecia. It causes severe hair loss and can lead to complete baldness. It is an autoimmune disease and can affect patients’ physical and mental lives greatly. JAK Inhibitors have been proven the most effective treatment option to treat LPP. This literature review aimed to analyze the effectiveness of JAK inhibitors in the management of LPP. In this review, we analyzed the ten most recent and comprehensive studies. The review has summarized existing case reports from clinical studies that have supported JAK inhibitors. The findings of the review show that JAK inhibitors are effective options for the treatment of LPP, however, there are still some concerns regarding the long-term safety of these drugs in the treatment of LPP. This review also highlights potential gaps in the literature and further need for research. Currently, there is a need for further research on the effectiveness of JAK inhibitors in the treatment of LPP.

Keywords : Lichen Planopilaris, Scarring Alopecia, Janus Kinase Inhibitors, Tofacitinib, Ruxolitinib, Baricitinib.

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe